News

Panel supports lower doses of novel insomnia drug

Publish date: May 23, 2013

 

FROM AN FDA ADVISORY PANEL MEETING

Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Zolpidem Linked to Higher Inpatient Fall Rates
MDedge Neurology
Acetazolamide and CPAP combined improve OSA at high altitude
MDedge Neurology
REM sleep problems predict Parkinson's, Lewy body dementia
MDedge Neurology
Older patients report frequent insomnia, sleep treatment use
MDedge Neurology
Preclinical brain amyloid deposition linked to poor sleep
MDedge Neurology
Robert Stickgold, PhD, Describes His Research Into the Relationship Between Sleep Disorders and Neurologic Disorders Such as Epilepsy
MDedge Neurology
Can Quality of Sleep Help Predict Productivity of NFL Draft Picks?
MDedge Neurology
Insomnia Symptoms May Be More Severe in Patients With Comorbid Chronic Pain
MDedge Neurology
FDA Requires Lower Dose for Certain Sleep Drugs
MDedge Neurology
Tips for Taking Sleeping Pills for Insomnia
MDedge Neurology